Live Breaking News & Updates on Zuma 7

Stay updated with breaking news from Zuma 7. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Recent Data on Axi-Cel in Lymphoma

Dr Leslie discusses two abstracts on axi-cel recently presented at ASH 2023: a subgroup analysis of ZUMA-7 and the 4-year follow-up from ZUMA-5. ....

Lori Leslie , Jamesk Mccloskey , Gloria Leslie , Peer Exchange , Research Programs , John Theurer Cancer Center , Hackensack University Medical Center , Hackensack University Medical , Associate Professor , Indolent Lymphoma , Mash 2023 , Zuma 7 , Axi Cel , Largeb Cell Lymphoma , Older Population , Cart Cell Therapy , Car T , Overall Survival , Indolent Lymphomas , Follicular Lymphoma , Marginal Zone Lymphoma , Relapsed Refractory Follicular Lymphoma ,

Dr Leslie on the Clinical Benefit of Axi-Cel in Elderly Patients With R/R LBCL

Lori A. Leslie, MD, discusses the efficacy and safety of second-line axicabtagene ciloleucel in elderly patients with high-risk, relapsed/refractory large B-cell lymphoma. ....

Gloria Leslie , Chronic Lymphocytic Leukemia Research Programs , Hackensack Meridian School Of Medicine , John Theurer Cancer Center , Indolent Lymphoma , Hackensack Meridian School , John Theurer Cancer Center , Axi Cel , Elderly Patients , Zuma 7 ,

Second-Line Axi-Cel Prolongs Survival Over SOC in Elderly Patients With R/R LBCL

The administration of axicabtagene ciloleucel in the second-line setting improved overall survival and progression-free survival vs standard-of-care treatment in patients with relapsed/refractory large B-cell lymphoma who are at least 65 years of age. ....

Noord Holland , United States , Marie Jos , American Society Of Hematology , Amsterdam University Medical Centers , Annual Meeting , Amsterdam University Medical , Cart Cell Therapy , Zuma 7 , 2023 Ash Annual Meeting , Relapsed Refractory Largeb Cell Lymphoma ,

Real-World Use of CAR T-Cell Therapy in Patients with Lymphoma

Explore the real-world application of CAR T-cell therapy in lymphoma treatment, from response rates to its role in first-line therapy. ....

International Prognostic Index , Largeb Cell Lymphoma , B Cell Lymphoma , Cart Cell Therapy , Lymphoma Treatment , Response Rate , Event Free Survival , Double Hit Lymphoma , Triple Hit Lymphoma , Zuma 7 , Belinda Trial , Transform Trial , Autologous Stem Cell Transplant , First Line Therapy , R Chop , High Risk Lymphoma ,

Diffuse Large B-Cell Lymphoma: Moving Novel Therapy to the Frontline Setting

Expert perspectives on recent efforts to move novel therapy from the relapsed/refractory to frontline setting of diffuse large B-cell lymphoma. ....

Translating Recent Evidence , Real World Management , Refractory Diffuse Largeb Cell Lymphoma , Largeb Cell Lymphoma , Moving Novel Therapy , Diffuse Largeb Cell Lymphoma , Relapsed Refractory Dlbcl , Rr Dlbcl , L Mind Study , L Mind Trial , Tl Mind , R Chop , Front Mind , Front Mind Study , Front Mind Trial , Zuma 7 , Zuma 12 , Zuma 23 , First Line Therapy , First Line Treatment , Frontline Therapy , Frontline Treatment , Asco 2023 , Asco Annual Meeting ,